Ruoxun Xiao, PRIMACYT Business Development Manager for Asia, represented PRIMACYT at the Beijing-Tianjin-Hebei International Biomedicine & Great Health Industry Development Conference 2023 on May. 29-31 in Cangzhou, Hebei.
Hebei Province is located in the middle of the North China Plain. It covers a land area of 188,500 square kilometers with a population of 74.7 million. Hebei is the home of many pharmaceutical and biomedical companies, including producers of chemical and biological drugs, traditional Chinese medicine, and medical devices. There are a total of 409 biomedical manufacturers and 1,801 medical equipment manufacturers based in Hebei. On May 29th, PRIMACYT has been invited to roundtable meeting “Discussing the Development Trend and Path of Pharmaceutical Industry”. The roundtable meeting was chaired by the leader of the Hebei Pharmaceutical Profession Association. Executives of nationally renowned biomedical enterprises talked about their vision and shared their experience about the innovative development of biomedical industry. Chinese Central Television (CCTV) has reported on the round table and the Opening Ceremony of the Conference emphasizing the importance of this conference.
During the meeting Ruoxun Xiao participated in one-to-one business matchmaking meetings with representatives of the local pharmaceutical companies and National laboratories. Ms. Xiao introduced our company, product and service portfolio, and possibilities for scientific cooperation. Several Chinese biomedical start-up companies and producers of Traditional Chinese Medicine expressed their interest in PRIMACYT’s assay portfolio, cell culture models and Contract Research Services. Follow-up visits are expected to take place in October and November this year. On the final day, PRIMACYT visited the local pharmaceutical enterprises in Cangzhou Bohai New Area Biomedical Industrial Park.
We seized the opportunity to meet new Chinese pharmaceutical companies and laboratories. Looking forward to fruitful co-operations and business partnerships in China in the future.